Your SlideShare is downloading. ×
0
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Ebs molecular markers june-pptx - copy
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Ebs molecular markers june-pptx - copy

755

Published on

Published in: Technology, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
755
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Evidence-Based SurgeryRole of Molecular Markers In Glioblastoma Sanmugarajah Paramasvaran John Fuller 14th June 2012 1
  • 2. Clinical Case• 61 yr gentleman• February 2012 – headache, left hemianopia• MRI as shown• Craniotomy for removal of tumour• HPE : Glioblastoma• WBRT and temozolamide 2
  • 3. Post Op Scan Recurrence in 10 weeks 3
  • 4. Clinical Questions: Does molecular markers in glioblastoma have dependable diagnostic, prognostic and treatment guidance value to be considered as routine investigation? 4
  • 5. Search strategy• P = Patients with glioblastoma• I = molecular markers• C=• O = better prognostic and treatment adviceSearch Keywords (exp MESH )1) “Molecular Markers” “2) “Glioblastoma” 5
  • 6. DatabaseMedline OvidScopusCochraneSearch Keywords (exp MESH )1) “Molecular Markers” “2) “Glioblastoma” 6
  • 7. Search Process 7
  • 8. 8
  • 9. Genetic Markers Tumour Markers 9
  • 10. 10
  • 11. 11
  • 12. Medline Ovid Search Results 12
  • 13. 13
  • 14. Scopus 14
  • 15. Cochrane Nil 15
  • 16. Selection Criteria• Glioblatoma• Molecular markers• Diagnostic , prognostic and therapeutic significanceExclusions: non GBM pathogenesis 16
  • 17. 30 papers from Medline Ovid 17
  • 18. 8 Papers from Scopus 18
  • 19. Levels of Evidence (NHMRC)Class lll – 21 papers 7 prospective cohorts 14 retrospective cohortsClass lV- 17 papers 19
  • 20. Conclusion MOLECULAR MARKERS SIGNIFICANCE MGMT PROGNOSTIC PREDICTIVE EGFR AMPLIFICATION DIAGNOSTIC IDH1 DIAGNOSTIC IN SECONDARY GBM (60-90%) IDH 1 & 2 BETTER PROGNOSIS PTEN DIAGNOSTIC OF PRIMARY GBMMarina N. Nikiforova, MD; Ronald L. Hamilton, MD, Arch Pathol Lab Med. 2011;135:558–568 20
  • 21. • Hegi and colleague reported , with temozolamide and RT MGMT Alive at 2 yrs Unmethylated 15% Methylated 49% 21
  • 22. 22
  • 23. IDH1 & 2 mutation - survival( 31 vs 15 months) 23
  • 24. Thank You 24

×